INVESTOR ALERT

Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) investors concerning the Company’s possible violations of federal securities laws.

On March 26, 2024, bluebird announced that it will restate financial statements for 2022 and for the first three quarters of both 2022 and 2023 in relation to the identification of embedded leases and the treatment of non-lease components contained in lease agreements with contract manufacturers. The Company further stated that it expects an increase in lease assets and lease liabilities, as well as an increase in non-cash interest expense in the restated periods.

On this news, bluebird’s stock price fell $0.16, or 11.8%, to close at $1.20 per share on March 26, 2024, thereby injuring investors.

If you purchased bluebird securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone] or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328457101/en/

The bluebird bio Stock at the time of publication of the news with a fall of -0,36 % to 1,238EUR on Tradegate stock exchange (28. März 2024, 14:13 Uhr).